DHI is found in 26 entries

DHI in polymers: 23 entries. Examples include: 1CZQ, 1ER8, 1MCB

DHI as free ligands, exist in 3 entries. Examples include 2EZ7, 3KL3, 3KOC

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Identifiers 3-(1H-imidazol-3-ium-4-yl)-D-alanine
(2R)-2-amino-3-(1H-imidazol-3-ium-4-yl)propanoic acid
Formula C6 H10 N3 O2
Molecular Weight 156.16 g/mol
Type D-peptide linking
Isomeric SMILES N[C@H](Cc1c[nH]c[nH+]1)C(O)=O
InChI InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/p+1/t5-/m1/s1

Chemical Details

Formal Charge 1
Atom Count 21
Chiral Atom Count 1
Chiral Atoms CA
Bond Count 21
Aromatic Bond Count 5
Leaving Atoms OXT H2 HXT

Drug Info: DrugBank

DrugBank ID DB00117   (Different stereochemistry)
Name L-Histidine
  • approved
  • nutraceutical
Description An essential amino acid that is required for the production of histamine. [PubChem]
  • (S)-4-(2-Amino-2-carboxyethyl)imidazole
  • (S)-a-Amino-1H-imidazole-4-propanoic acid
  • (S)-alpha-amino-1H-Imidazole-4-propanoic acid
  • (S)-alpha-Amino-1H-imidazole-4-propionic acid
  • (S)-α-amino-1H-Imidazole-4-propanoic acid
  • H
  • His
  • Histidine
  • L-(-)-Histidine
  • L-(−)-histidine
  • L-Histidin
  • L-Histidine
Brand Names
  • Aminosyn 10%
  • Aminosyn 5%
  • Aminosyn 7%
  • Aminosyn 8.5%
  • Travasol
  • Vamin 18 Electrolyte-free
Affected Organism Humans and other mammals
Indication The actions of supplemental L-histidine are entirely unclear. It may have some immunomodulatory as well as antioxidant activity. L-histidine may be indicated for use in some with rheumatoid arthritis. It is not indicated for treatment of anemia or uremia or for lowering serum cholesterol.
Pharmacology Is found abundantly in hemoglobin; has been used in the treatment of rheumatoid arthritis, allergic diseases, ulcers and anemia. A deficiency can cause poor hearing.
Mechanism of action Since the actions of supplemental L-histidine are unclear, any postulated mechanism is entirely speculative. However, some facts are known about L-histidine and some of its metabolites, such as histamine and trans-urocanic acid, which suggest that supplemental L-histidine may one day be shown to have immunomodulatory and/or antioxidant activities. Low free histidine has been found in the serum of some rheumatoid arthritis patients. Serum concentrations of other amino acids have been found to be normal in these patients. L-histidine is an excellent chelating agent for such metals as copper, iron and zinc. Copper and iron participate in a reaction (Fenton reaction) that generates potent reactive oxygen species that could be destructive to tissues, including joints.
L-histidine is the obligate precursor of histamine, which is produced via the decarboxylation of the amino acid. In experimental animals, tissue histamine levels increase as the amount of dietary L-histidine increases. It is likely that this would be the case in humans as well. Histamine is known to possess immunomodulatory and antioxidant activity. Suppressor T cells have H2 receptors, and histamine activates them. Promotion of suppressor T cell activity could be beneficial in rheumatoid arthritis. Further, histamine has been shown to down-regulate the production of reactive oxygen species in phagocytic cells, such as monocytes, by binding to the H2 receptors on these cells. Decreased reactive oxygen species production by phagocytes could play antioxidant, anti-inflammatory and immunomodulatory roles in such diseases as rheumatoid arthritis.
This latter mechanism is the rationale for the use of histamine itself in several clinical trials studying histamine for the treatment of certain types of cancer and viral diseases. In these trials, down-regulation by histamine of reactive oxygen species formation appears to inhibit the suppression of natural killer (NK) cells and cytotoxic T lymphocytes, allowing these cells to be more effective in attacking cancer cells and virally infected cells.
Route of administration intravenous
  • Dietary Supplements
  • Micronutrients
  • Conditionally Essential Amino Acids
  • Supplements
CAS number 71-00-1
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682